Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

Clinical activity of brentuximab vedotin(BV), an anti- CD30 antibody-drug conjugate, has been demonstrated in relapsed/refractory classical Hodgkin Lymphoma(R/R cHL) in pivotal phase I and phase II studies.[1][1],[2][2] Adverse events ascribed to BV as single agent are mostly mild and reversible.[3